PremiumThe FlyZealand Pharma to pay $350M to Roche in petrelintide collaboration, license pact William Blair upgrades Zealand to Outperform on recent selloff Zealand Pharma upgraded to Outperform from Market Perform at William Blair PremiumThe FlyZealand Pharma price target lowered to DKK 750 from DKK 755 at Morgan Stanley Zealand Pharma Reports Transformative Year with Strong R&D Focus ZLDPF Earnings this Week: How Will it Perform? PremiumThe FlyZealand Pharma says FDA issues CRL for glepaglutide NDA Zealand Pharma announces first participant enrolled in ZUPREME-1 Zealand Pharma upgraded to Hold from Sell at Danske Bank 
